<DOC>
	<DOCNO>NCT02823561</DOCNO>
	<brief_summary>Obesity one great public health challenge 21st century . Its prevalence triple many country European Region since 1980s , number affect continue rise alarm rate . In addition cause various physical disability psychological problem , excess weight drastically increase person 's risk develop number noncommunicable disease include cardiovascular disease , cancer diabetes , association metabolic syndrome . The risk develop one disease ( co-morbidity ) also increase increase body weight . Every year grow number patient tend suffer severe obesity difficulty lose weight even restrict diet exercise . Garcinia mangostana ( Sphaeranthus indicus extract ) know antioxidant property ; new evidence point promise effect prevention lipogenesis promotion lipolysis . Currently scientific literature one paper , Stern et al. , show association Garcinia mangostana assumption low-calorie diet . This work demonstrate significant reduction weight loss , compare placebo group , due use Garcinia mangostana . Aim present study evaluation safety efficacy weight loss severe obese patient . Also cardiometabolic parameter flogosys serum indicator evaluate 6 month therapy low calory diet alone association Garcinia mangostana extract .</brief_summary>
	<brief_title>Garcinia Mangostana Extracts Management Weight Loss</brief_title>
	<detailed_description>After screen visit evaluation inclusion / exclusion criterion sign inform consent ( Visit 1 ) , patient randomize ( Visit 2 ; Time 0 ; Baseline ) ( 1 : 1 ) receive two different treatment duration 26 week : 1. low-calorie balance diet consistent exercise ( control group ) 2. balance low-calorie diet regular exercise combination assumption Garcinia mangostana ( treatment group ) Throughout duration study , every eight week , unless otherwise indicated specialist , subject expect nutritional endocrinological visit anthropometric parameter check ( body composition ) compliance therapy ( dietary / physical activity diary ) . Also bood sample test perform evaluate electrocardiogram , lipid profile , glucose tolerance , hormonal parameter , inflammatory bone marker .</detailed_description>
	<mesh_term>Weight Loss</mesh_term>
	<mesh_term>Obesity , Morbid</mesh_term>
	<criteria>Obesity : BMI &gt; 35 kg/m2 . Stable medical therapy comorbidities least 6 month Hormonal replacement therapy Hyperprolactinaemia /or endocrine hypothalamicpituitary disease ( empty sella syndrome expansive pituitary disorder evaluate MRI ) Any condition medical judgment precludes patient safety</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>